A meta-analysis of phase III randomized controlled trials with novel oral anticoagulants in atrial fibrillation: Comparisons between direct thrombin inhibitors vs. factor Xa inhibitors and different dosing regimens

Thrombosis Research

Volumn 134, Issue 6, 2014, Pages 1253-1264

  Providência, Rui ^a   Grove, Erik Lerkevang ^b   Husted, Steen ^b   Barra, Sérgio ^c   Boveda, Serge ^d   Morais, João ^e  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c PAPWORTH HOSPITAL   (United Kingdom)

^d CLINIQUE PASTEUR   (France)

^e Hospital de Santo Andre   (Portugal)

Author keywords

Anticoagulants; Atrial fibrillation; Bleeding; Coumarins; NOAC; Stroke

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN; EDOXABAN; RIVAROXABAN; THROMBIN INHIBITOR; WARFARIN; ANTITHROMBIN;

ACUTE HEART INFARCTION; ARTICLE; BLEEDING; BRAIN EMBOLISM; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; COMPARATIVE STUDY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HUMAN; META ANALYSIS; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); THROMBOEMBOLISM; AGED; ATRIAL FIBRILLATION; CHEMICALLY INDUCED; COMORBIDITY; DRUG ADMINISTRATION; FEMALE; HEMORRHAGE; MALE; ORAL DRUG ADMINISTRATION; RISK FACTOR; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; ANTITHROMBINS; ATRIAL FIBRILLATION; CAUSALITY; CLINICAL TRIALS, PHASE III AS TOPIC; COMORBIDITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FACTOR XA INHIBITORS; FEMALE; HEMORRHAGE; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; STROKE; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 84915793225     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2014.10.002     Document Type: Article

References (29)

1. E.J. Benjamin, P.A. Wolf, R.B. D'Agostino, H. Silbershatz, W.B. Kannel, and D. Levy Impact of atrial fibrillation on the risk of death: the Framingham Heart Study Circulation 98 10 1998 946 952
2. P.A. Wolf, T.R. Dawber, H.E. Thomas Jr., and W.B. Kannel Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study Neurology 28 10 1978 973 977
3. P. Petersen, G. Boysen, J. Godtfredsen, E.D. Andersen, and B. Andersen Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study Lancet 1 1989 175 179
4. H.C. Diener, J. Eikelboom, C.B. Granger, and W. Hacke The king is dead (warfarin): direct thrombin and factor Xa inhibitors: the next Diadochian War? Int J Stroke 7 2 2012 139 141
5. R. De Caterina, S. Husted, L. Wallentin, F. Andreotti, H. Arnesen, and F. Bachmann New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper J Am Coll Cardiol 59 16 2012 1413 1425
6. D. Menzies Systematic reviews and meta-analyses Int J Tuberc Lung Dis 15 5 2011 582 593
7. D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman, and PRISMA Group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement Ann Intern Med 151 2009 264 269
8. A.P. Verhagen, H.C. de Vet, R.A. de Bie, A.G. Kessels, M. Boers, and L.M. Bouter The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus J Clin Epidemiol 51 1998 1235 1241
9. H.C. Bucher, G.H. Guyatt, L.E. Griffith, and S.D. Walter The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials J Clin Epidemiol 50 6 1997 683 691
10. Japanese Circulation Society Joint Working Group Guidelines for pharmacotherapy of atrial fibrillation (JCS 2008): Digest version Circ J 74 2010 2479 2500
11. J.P.T. Higgins, and S. Green Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] 2011 The Cochrane Collaboration [Available from: www.cochrane-handbook.org ]
12. J. Brok, K. Thorlund, J. Wetterslev, and C. Gluud Apparently conclusive meta-analyses may be inconclusive-Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses Int J Epidemiol 38 1 2009 287 298
13. S.B. Olsson Executive Steering Committee of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial Lancet 362 9397 2003 1691 1698
14. G.W. Albers, H.C. Diener, L. Frison, M. Grind, M. Nevinson, and S. Partridge Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial JAMA 293 6 2005 690 698
15. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren, and A. Parekh Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 12 2009 1139 1151
16. M.R. Patel, K.W. Mahaffey, J. Garg, G. Pan, D.E. Singer, and W. Hacke Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 10 2011 883 891
17. C.B. Granger, J.H. Alexander, J.J. McMurray, R.D. Lopes, E.M. Hylek, and M.J.J. Hanna Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 11 2011 981 992
18. M. Hori, M. Matsumoto, N. Tanahashi, S. Momomura, S. Uchiyama, and S. Goto Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation - the J-ROCKET AF study - Circ J 76 9 2012 2104 2111
19. R.P. Giugliano, C.T. Ruff, E. Braunwald, S.A. Murphy, S.D. Wiviott, and J.L. Halperin Edoxaban versus warfarin in patients with atrial fibrillation N Engl J Med 369 22 2013 2093 2104
20. C.T. Ruff, R.P. Giugliano, E. Braunwald, E.B. Hoffman, N. Deenadayalu, and M.D. Ezekowitz Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials Lancet 383 9921 2014 955 962
21. F. Dentali, N. Riva, M. Crowther, A.G. Turpie, G.Y. Lip, and W. Ageno Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature Circulation 126 20 2012 2381 2391
22. A.J. Camm, G.Y. Lip, R. De Caterina, I. Savelieva, D. Atar, and S.H. Hohnloser 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation-developed with the special contribution of the European Heart Rhythm Association Europace 14 10 2012 1385 1413
23. T.J. Cleophas, and A.H. Zwinderman Meta-analysis Circulation 115 2007 2870 2875
24. W.M. O'Neil, S.A. Welner, and G.Y. Lip Do open label blinded outcome studies of novel anticoagulants versus warfarin have equivalent validity to those carried out under double-blind conditions? Thromb Haemost 109 3 2013 497 503
25. J.W. Eikelboom, and J.I. Weitz Anticoagulation therapy. Dabigatran and risk of myocardial infarction Nat Rev Cardiol 9 5 2012 260 262
26. A. Hoffman, and P.R. Galle Gastrointestinal disorders and dabigatran Scand J Gastroenterol 48 1 2013 9 16
27. P. Sardar, S. Chatterjee, and D. Mukherjee Efficacy and safety of new oral anticoagulants for extended treatment of venous thromboembolism: systematic review and meta-analyses of randomized controlled trials Drugs 73 2013 1171 1182
28. S.S. Adam, J.R. McDuffie, T.L. Ortel, and J.W. Williams Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review Ann Intern Med 157 2012 796 807
29. A. Dogliotti, E. Paolasso, and R.P. Giugliano Novel oral anticoagulants in atrial fibrillation: a meta-analysis of large, randomized, controlled trials vs warfarin Clin Cardiol 36 2013 61 67